Patrys

PAB.AX

Tags: AU Healthcare Biotechnology

Patrys Limited Price (PAB.AX)

Stock Price

Low: Year Low

High: Year High

Market Cap

Fetching Data...

Enterprise Value

Fetching Data...

Shares Outstanding

2,055,750,235

(0.0169)%

Market Cap of Patrys (PAB.AX)

Market cap:

As of , PAB.AX has a market cap of . This makes PAB.AX the 1528th most valuable company in the AU by market cap. Market capitalization, or market cap, is the total value of a company's outstanding shares of stock, calculated by multiplying the current stock price by the total number of shares.

Year

Beginning Of Year

End Of Year

YOY Change

Community Sentiment 0 votes

↑ 0% ↓ 0%

Description

Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. Its lead technology is Deoxymab 3E10, a DNA damage-repair antibody that penetrates cell nuclei. The company also focuses on developing PAT-DX1, an antibody fragment for the treatment of primary and secondary brain cancer. In addition, it is developing PAT-DX3, a full-sized antibody that has DNA-binding and DNA damage repair blocking properties of PAT-DX1 used for tissue distribution, pharmacokinetic profile, etc.; an... Read More

Sector: Healthcare

Previous Close Fetching Data...
Range $0.002-0.01
Market Cap 4.11M
Enterprise Value No Data
Avg Volume Fetching Data...
P/E Ratio Fetching Data...
Dividend Yield Fetching Data...

Industry: Biotechnology

ceo: Dr. James A. Campbell B.Sc., MBA, Ph.D.
IPO Date: July, 13, 2007
Country: AU
Currency: AUD
Headquaters: Melbourne, VIC
Employees: 15

- Revenue from each product or segment:

Product or Segment	Value:	% - Total	Last 3Y:

- Revenue by Region

Product or Segment	Value:	% - Total	Last 3Y: